Autophagy activation by novel inducers prevents BECN2-mediated drug tolerance to cannabinoids by Kuramoto, Kenta et al.
BASIC RESEARCH PAPER
Autophagy activation by novel inducers prevents BECN2-mediated drug tolerance
to cannabinoids
Kenta Kuramotoa,y,yy, Nan Wanga,b,y, Yuying Fana,c, Weiran Zhanga, Frank J. Schoenend, Kevin J. Frankowskie,
Juan Maruganf, Yifa Zhouc, Sui Huanga, and Congcong Hea
aDepartment of Cell and Molecular Biology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; bKey Laboratory of Industrial
Microbiology, Ministry of Education and Tianjin City, College of Biotechnology, Tianjin University of Science and Technology, Tianjin, China; cSchool of
Life Sciences, Northeast Normal University, Changchun, Jilin, China; dHiguchi Biosciences Center, University of Kansas, Lawrence, KS, USA; eUNC
Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; fDivision of Pre-Clinical Innovation, National Center for
Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA
ARTICLE HISTORY
Received 17 December 2015
Revised 29 April 2016
Accepted 4 May 2016
ABSTRACT
Cannabinoids and related drugs generate profound behavioral effects (such as analgesic effects) through
activating CNR1 (cannabinoid receptor 1 [brain]). However, repeated cannabinoid administration triggers
lysosomal degradation of the receptor and rapid development of drug tolerance, limiting the medical use
of marijuana in chronic diseases. The pathogenic mechanisms of cannabinoid tolerance are not fully
understood, and little is known about its prevention. Here we show that a protein involved in
macroautophagy/autophagy (a conserved lysosomal degradation pathway), BECN2 (Beclin 2), mediates
cannabinoid tolerance by preventing CNR1 recycling and resensitization after prolonged agonist
exposure, and deletion of Becn2 rescues CNR1 activity in mouse brain and conveys resistance to analgesic
tolerance to chronic cannabinoids. To target BECN2 therapeutically, we established a competitive
recruitment model of BECN2 and identified novel synthetic, natural or physiological stimuli of autophagy
that sequester BECN2 from its binding with GPRASP1, a receptor protein for CNR1 degradation. Co-
administration of these autophagy inducers effectively restores the level and signaling of brain CNR1 and
protects mice from developing tolerance to repeated cannabinoid usage. Overall, our findings
demonstrate the functional link among autophagy, receptor signaling and animal behavior regulated by
psychoactive drugs, and develop a new strategy to prevent tolerance and improve medical efficacy of
cannabinoids by modulating the BECN2 interactome and autophagy activity.
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Introduction
Cannabinoids and related drugs, such as the marijuana-derived
ingredients, generate profound behavioral effects (such as anal-
gesic effects) that are therapeutic in many pathological condi-
tions, including neurodegeneration, digestive disorders,
spasticity, and chronic and cancer-related pain.1-4 However,
long-term administration of cannabinoids for either medical or
recreational purposes induces rapid development of tolerance
(a demonstration of physical dependence), which is a limitation
and concern of its medical use and may lead to addiction and
withdrawal symptoms.5,6 Clinical data showed that 9% of adult
cannabis users, and 17% of adolescent users, develop depen-
dence and addiction after repeated dosage,6 which is not trivial
given the widespread usage of illicit cannabinoids in many
countries. Yet the pathogenic mechanisms of cannabinoid tol-
erance are not fully understood, and little is known about its
prevention methods. Consequently, only a very small number
of cannabinoid therapeutics have been approved and used clin-
ically in the market in limited regions; for example, the
cannabis medication for spasticity, Sativex, is prescribed as an
oromucosal spray to ensure slow blood delivery and is adminis-
tered at relatively low doses.
The effects of cannabinoids are mediated by binding and acti-
vation of a G protein-coupled receptor (GPCR), CNR1/CB1
(cannabinoid receptor 1 [brain]), and chronic exposure to canna-
binoids results in lysosomal trafficking and degradation of CNR1,
which causes diminished cellular responses and requires higher
doses to produce the same effects.7 Therefore, retaining the
functionality of CNR1 may play an important role in the preven-
tion of cannabinoid tolerance, especially in clinical applications. A
recently identified autophagy gene, Becn2 (Beclin 2), which
belongs to the Beclin (coiled-coil, myosin-like BCL2-interacting
protein) family, may link CNR1-regulated cell signaling and
animal behavior to the autophagy pathway.8 Autophagy is an
essential catabolic process that breaks down damaged or unneces-
sary structures in lysosomes, and the resulting metabolites are
recycled and reused for new protein synthesis and energy produc-
tion. Autophagy is intensely induced by physiological stimuli or
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stress, such as starvation9 and physical exercise,10 and malfunction
of autophagy has been implicated in a variety of diseases, including
neurodegeneration, cardiovascular diseases, cancer and metabolic
disorders.11-13 In addition to a role in autophagy, BECN2 is also
essential for agonist-induced lysosomal degradation of a group of
specific GPCRs, including CNR1, DRD2 (dopamine receptor D2)
and OPRD1 (opioid receptor, delta 1).8 In vitro biotin protection
degradation data suggest that BECN2 mediates the degradation of
these GPCRs by binding to GPRASP1/GASP1 (G protein-coupled
receptor associated sorting protein 1),8 a receptor protein that
degrades GPCRs independently of ubiquitination and certain
components of the canonical endosomal sorting complex required
for transport (ESCRT) machinery.14-18
It is unclear whether BECN2 regulates the downstream
events of these GPCRs in response to chronic agonist exposure,
including receptor resensitization, signaling cascades and drug-
responsive behaviors in vivo, which are important questions
especially when many of the GPCRs in this specific group are
targets of psychoactive drugs, such as CNR1. In addition, the
function, genetic basis and molecular mechanism of autophagy
in the regulation of drug tolerance and dependence after
repeated usage remain mysterious. It is also unknown how the
autophagy pathway crosstalks with drug-responsive GPCR sig-
naling and behavioral regulation, and whether BECN2 plays a
role in the process. Here we found that BECN2 is essential for
the development of analgesic tolerance after chronic cannabi-
noid exposure by preventing CNR1 recycling and resensitiza-
tion in mice. We discovered that activation of autophagy
restores CNR1 function and regulates cannabinoid analgesia
through BECN2, and also identified novel synthetic and natural
agents to prevent cannabinoid tolerance by modulating the
BECN2 interactome and autophagy activity. Our findings dem-
onstrated for the first time a new functional link among
autophagy, drug responses and behaviors regulated by psycho-
active substances, and opened up a new direction to potentially
improve medical efficacy of cannabinoids in many circumstan-
ces such as pain management.
Results
Becn2C/¡ heterozygous knockout mice are resistant to
analgesic tolerance induced by repeated cannabinoid
dosage
We hypothesized that in response to prolonged cannabinoid
exposure, BECN2 mediates the degradation and rapid deactiva-
tion of CNR1. To test this hypothesis, we sought to use the
Becn2C/¡ heterozygous knockout (KO) mice, because becn2¡/¡
homozygotes rarely survive the embryonic development period.
We treated Becn2C/¡mice and wild-type (WT) littermates daily
for 14 d with WIN55,212–2 (WIN), a synthetic cannabinoid
drug and CNR1 agonist, and analyzed the levels of CNR1 in
the brain. Compared to WT mice, Becn2C/¡ mice maintained a
significantly higher level of brain CNR1 after 14 d of chronic
cannabinoid treatment (Fig. 1A), in addition to a trend of
increased steady-state CNR1 levels under normal conditions
(with DMSO treatment), which suggests that BECN2 loss-of-
function increases the availability of CNR1 after repeated
agonist dosage.
To study whether BECN2 functions in CNR1-regulated
behavioral responsiveness following chronic cannabinoid
treatment, we analyzed the anti-nociceptive (i.e., anti-pain)
effect of WIN as a readout by analgesic tolerance tests
(Fig. 1B), using WT mice and mice heterozygous for Becn2, or
for Becn1, another Beclin family member that does not bind
GPRASP1 or regulate GPCR degradation as a control. There
were no genotype differences either in basal pain sensitivity to
infrared heat-generated pain (agonist-free, d 0) (Fig. 1C, Video
S1-S3), or in analgesic effects of acute WIN treatment prior to
chronic WIN administration (d 1) (Fig. 1D, Video S4-S6).
However, 14 d of repeated WIN dosage markedly decreased
its analgesic effect in WT and Becn1C/¡ mice, but not in
Becn2C/¡ mice (d 14) (Fig. 1D, Video S7-S9), suggesting that
Becn2C/¡ mice are resistant to analgesic tolerance induced by
prolonged cannabinoid exposure. Notably, body weight of
mice of all genotypes remained constant during chronic WIN
treatment (Fig. S1). Thus, these data demonstrate that BECN2
downregulates the level of brain CNR1 after prolonged WIN
treatment, and BECN2 loss of function protects animals from
developing analgesic tolerance to repeated exposure of canna-
binoid drugs.
CNR1 is resensitized at the cell surface upon BECN2 loss
We next sought to investigate the cellular mechanism
underlying the behavioral protection against tolerance
upon loss of BECN2. Published data have shown that
BECN2 is required for agonist-induced lysosomal transport
of OPRD1, another GPRASP1-bound GPCR, which is relo-
calized to the plasma membrane upon loss of BECN2.8
However, it is unknown whether in the absence of BECN2
these recycled receptors are functional, or whether BECN2
also plays a role in the trafficking, recycling and signaling
of CNR1 after prolonged agonist exposure. Here we pro-
posed that BECN2 depletion stabilizes CNR1 levels by pro-
moting its recycling and resensitization at the cell surface,
and tested this hypothesis from 3 aspects. We first fol-
lowed the intracellular trafficking of CNR1 in response to
agonists, by examining its colocalization with endosome
(EEA1) or lysosome (LAMP1) markers in the absence of
BECN2. By pulse-labeling cell-surface CNR1 with anti-
body, we found that compared to basal conditions
(0 min), in a significantly higher number of cells treated
with control siRNA, CNR1 was transported to endosomes
after 30 min of WIN treatment and to lysosomes after
60 min, whereas in cells transfected with Becn2 siRNA,8
instead of being transported to lysosomes for degradation,
internalized CNR1 was trapped in endosomal structures
even after 60 min of WIN treatment (Fig. 2A, Fig. S2A).
In addition, in Becn2 siRNA-treated cells the endocytosed
CNR1 relocalized to the cell surface after 30 min of ago-
nist removal and antagonist treatment (Fig. 2B). Thus,
these data demonstrate that loss of BECN2 leads to accu-
mulation of CNR1 in the endosomes and its eventual recy-
cling to the plasma membrane.
Next, to study whether the recycled CNR1 caused by
BECN2 depletion is resensitized and functional, we examined
the signaling pathways downstream of CNR1 at both
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biochemical and cellular levels. CNR1 is coupled to the GNAI/
Gi/o protein, and CNR1 activation inhibits the ADCY/adenylyl
cyclase activity and cyclic adenosine monophosphate (cAMP)
production, while activating the mitogen-activated protein
kinase (MAPK) pathways, including MAP2K1 (mitogen-acti-
vated protein kinase 1)/MEK1-MAP2K2/MEK2 and MAPK8/
JNK1-MAPK9/JNK2 cascades.7,19 Thus, we measured canna-
binoid-induced cAMP suppression (Fig. 2C) and MAPK cas-
cade phosphorylation (Fig. 2D) in cell lines and primary
MEFs (mouse embryonic fibroblasts) following prolonged
agonist treatment. We found that the intracellular cAMP level
was reduced in Becn2 siRNA-treated cells compared to control
cells (Fig. 2C), which suggests an increased level of functional
CNR1 at the cell surface and is an indication of CNR1 resensi-
tization upon loss of BECN2. Furthermore, we detected a
higher level of cannabinoid-induced phosphorylation of
MAP2K1/2 and MAPK8/9 in Becn2 KO primary MEFs
(Fig. 2D), as well as a trend of higher MAP2K1/2 and
MAPK8/9 phosphorylation in the brain of Becn2C/¡ mice
(Fig. S2B), than in WT MEFs or brain, suggesting higher
CNR1 functionality after chronic agonist exposure in the
absence of BECN2. Overall, these data suggest that loss of
BECN2 leads to CNR1 resensitization.
Competitive recruitment model of BECN2 and
identification of novel brain-penetrable autophagy
inducers
Accordingly, an important translational question is how to
reduce BECN2 activity to maintain CNR1 sensitivity and pre-
vent drug tolerance induced by repeated cannabinoid exposure.
To avoid the technical difficulty and risk of directly deleting
Becn2 in vivo (such as by injecting shRNAs or CRISPR con-
structs), which may disrupt BECN2-regulated autophagy, we
developed and tested a novel and more convenient strategy to
achieve the same goal via modulating the BECN2 interactome,
which will not affect the essential autophagy function of
BECN2 (Fig. 3A). As previously reported,8 BECN2 is present in
2 distinct protein complex pools, the BECN2-class III phospha-
tidylinositol 3-kinase complex for autophagy, and the BECN2-
GPRASP1-GPCR complex in which BECN2-GPRASP1 binding
is required for GPCR degradation. Thus, we hypothesized that
BECN2 is a limiting factor that regulates the balance between
the 2 lysosomal degradation pathways, and that competitive
recruitment of BECN2 to the autophagy machinery by activat-
ing autophagy prevents it from functioning in CNR1 downre-
gulation and thus restores CNR1 functionality and reverses
Figure 1. Loss of BECN2 confers resistance to analgesic tolerance induced by chronic usage of cannabinoid drugs. (A) Brain samples from Becn2C/¡ heterozygous knock-
out (KO) and WT mice were collected after 14 d of prolonged treatment of vehicle or the synthetic cannabinoid drug WIN55,212–2 (WIN). CNR1 levels were analyzed by
western blot of brain lysates (left) and quantified (right). Representative images of 3 mice in each group are shown. (B) Chronic cannabinoid treatment scheme, described
in Materials and methods. Briefly, mice were injected with WIN for 14 d, and analgesic tolerance was measured without WIN treatment on day 0, and after 1-h WIN
treatment on d 1 and d 14. (C) Baseline pain sensitivity of WT and Becn2C/¡ mice before chronic WIN treatment (day 0, agonist-free). N  16 mice/group.
(D) Becn2C/¡ mice show resistance to analgesic tolerance to chronic WIN treatment. Becn2C/¡, Becn1C/¡ and WT mice were treated with daily WIN for 14 d, and the anal-
gesic effect of WIN was analyzed as in (B). Statistics are comparing the same genotype on d 1 and d 14. N D 9–13 mice/group. Results represent mean § s.e.m.
, P < 0.05; , P < 0.01; , P < 0.001; NS, not significant (t-test).
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Figure 2. BECN2 depletion triggers resensitization of endocytosed CNR1 at the plasma membrane. (A) Immunofluorescence imaging (upper) and quantification (lower) of
the effects of nontargeting control (NC) or Becn2 siRNA on the fate of endocytosed CNR1. HEK293 cells stably expressing FLAG-CNR1 were fed with anti-FLAG antibody,
treated with the agonist WIN for 30 or 60 min and immunostained as in Materials and methods. Green, FLAG-CNR1; red, EEA1 or LAMP1. Percentages of cells with CNR1-
EEA1 or CNR1-LAMP colocalization in >200 cells per experiment were quantified from 4 independent experiments. (B) Becn2 knockdown promotes CNR1 recycling to the
cell surface after prolonged agonist exposure, analyzed by immunofluorescence imaging of FLAG-CNR1. HEK293 FLAG-CNR1 cells were fed with anti-FLAG antibody, and
treated with WIN for 30 or 180 min or with WIN for 140 min followed by agonist washout and antagonist (rimonabant) treatment for 30 min. Scale bar: 20 mm. (C) Becn2
knockdown suppresses the ADCY/adenylyl cyclase activity downstream of CNR1 after prolonged agonist exposure. HEK293 FLAG-CNR1 cells transfected with the indicated
siRNAs were treated either with vehicle for 120 min, or with WIN for 120 min to induce CNR1 internalization and degradation, followed by agonist washout and antago-
nist (rimonabant) treatment for 30 min to trigger CNR1 recycling and another 20 min treatment of WIN to activate any CNR1 at the cell surface. Results represent mean§
s.e.m of 3 independent experiments. (D) BECN2 depletion increases cannabinoid-induced CNR1 signaling after prolonged exposure. Becn2C/C, Becn2C/¡ or becn2¡/¡ pri-
mary MEFs were treated as in (C). Phosphorylation of MAP2K and MAPK8/9 downstream of CNR1 was analyzed by western blot (upper) and quantified from 3 indepen-
dent experiments (lower). Results represent mean§s.e.m. , P < 0.05; , P < 0.01; , P < 0.001; NS, not significant (t-test).
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Figure 3. Identification of novel brain-penetrable autophagy-inducing compounds. (A) Competitive recruiting model of BECN2 by the 2 lysosomal degradation pathways:
inducing autophagy shunts BECN2 away from the BECN2-GPRASP1 complex, and thus attenuates lysosomal degradation of CNR1 and maintains its responsiveness. Red
arrows, pro-autophagy; black arrows, pro-CNR1 downregulation. PtdIns3K, phosphatidylinositol 3-kinase. (B) Chemical structure of ML246. (C and D) Representative
images (C) and quantification (D) of GFP-LC3 puncta in HeLa cells stably expressing GFP-LC3 cultured for 3 h in normal or starvation medium, or treated with Rg2 or
ML246 in normal medium for 3 h or 16 h, in the presence or absence of bafilomycin A1 (BafA1). Results represent mean § s.e.m. Statistics are comparing the indicated
value with or without BafA1 to the one under the normal condition. Blue, DAPI; scale bar: 20 mm. (E) Representative images (left) and quantification (right) of GFP-LC3
puncta in the brain of GFP-LC3 transgenic mice injected with vehicle or ML246. Results represent mean § s.d. Scale bar: 25 mm. N>100 cells or N  4 mice.
, P < 0.01; , P < 0.001 (t-test).
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drug tolerance. To test this hypothesis, we first examined
whether autophagy activation by brain-penetrable inducers
inhibits the BECN2-GPRASP1 interaction. From a small-mole-
cule library screen20 and a phytochemical screen (Y. Fan, A.
Rocchi, N. Wang, W. Zhang, R. Vassar, Y. Zhou and C. He,
manuscript in preparation), we identified 2 novel brain-pene-
trable autophagy-inducing compounds: ML246 (also named
metarrestin based on its anti-metastasis effects in cancer,20
Fig. 3B), a synthetic small molecule derived from a high-
throughput screen against a pan-cancer cellular marker; and
Rg2,21 a 785 Da natural steroid glycoside compound isolated
from Panax ginseng by analytical chemistry approaches.
To determine autophagy activation by the 2 compounds, we
analyzed several markers of autophagy induction, including
formation of autophagosomes in cells and transgenic mice
expressing GFP-tagged MAP1LC3/LC3 (microtubule-associ-
ated protein 1 light chain 3; an autophagosome marker),9 deg-
radation of SQSTM1/p62 (sequestosome 1; an autophagy
receptor and substrate protein), and conversion of LC3 from
the non-lipidated form (LC3-I) to the phagophore- and auto-
phagosome-associated lipidated form (LC3-II). Both com-
pounds markedly increased numbers of GFP-LC3 puncta
(representing autophagosomes) and decreased levels of
SQSTM1 in HeLa cells and in mouse brain, as potently as star-
vation (Fig. 3C-E, Fig. S3A-C), although as previously
reported22 we did not detect significant changes in LC3-II con-
version in brain. In addition, when cotreated with the lyso-
somal inhibitor bafilomycin A1, ML246 or Rg2 led to more
accumulation of GFP-LC3 puncta, LC3-II and SQSTM1 com-
pared to normal conditions (Fig. 3C-D, Fig. S3D), suggesting
an increased level of autophagic flux induced by either com-
pound. Therefore, both agents are effective autophagy inducers
in vitro and in vivo.
Activation of autophagy pharmacologically or
physiologically attenuates BECN2-GPRASP1 binding,
dependent on the early initiation step of autophagy
Based on our model, we subsequently examined the effect of
the ML246 and Rg2 inducers on the BECN2-GPRASP1 interac-
tion in vitro and in mouse brain. We found that autophagy
induction either pharmacologically with ML246 or physiologi-
cally with starvation medium for 3 h potently blocked co-
immunoprecipitation of endogenous GPRASP1 by BECN2 in
HEK293 cells (Fig. 4A). Importantly, early initiation of
autophagy is required for the sequestration of BECN2 from
GPRASP1 binding by autophagy inducers, as the BECN2-
GPRASP1 complex remained intact during starvation or
ML246 treatment after knockdown of any member in the
upstream ATG13-RB1CC1/FIP200-ULK1 kinase complex
Figure 4. Autophagy induction by synthetic, natural or physiological inducers disrupts the BECN2-GPRASP1 interaction in vitro and in vivo, dependent on the upstream
ULK1 kinase complex. (A) Co-immunoprecipitation (co-IP) of endogenous human GPRASP1 with FLAG-human BECN2 in HEK293 cells treated with normal or starvation
medium, or normal medium with ML246 for 3 h. The same co-IPs were also performed in HEK293 cells transfected with siRNAs against Atg13, Rb1cc1 or Ulk1. The lower
panel shows the siRNA knockdown efficiency of each gene. (B) Co-IP of endogenous GPRASP1 with endogenous BECN2 using brain lysates from WT mice treated with
vehicle, ML246 or Rg2, or with 48-h starvation. Lysates in each group were pooled from 3 mice.
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essential for autophagy induction (Fig. 4A).23-26 Furthermore,
injection of ML246 or Rg2 in vivo to WT mice, as well as 48-h
starvation, dramatically decreased the binding between endoge-
nous BECN2 and endogenous GPRASP1 in mouse brain
(Fig. 4B). Overall, these data suggest that both physiological
and novel pharmacological autophagy inducers attenuate
BECN2-GPRASP1 binding, which is dependent on the early
initiating step of autophagy and supports our competitive
recruitment model of BECN2. Thus, autophagy inducers serve
as new candidates in the prevention of receptor downregulation
and cannabinoid tolerance to prolonged exposure.
Synthetic, natural or physiological autophagy inducers
prevent WT mice from analgesic tolerance after chronic
cannabinoid usage
We then tested the efficacy of ML246 and Rg2 in the mainte-
nance of cannabinoid analgesia in WT mice. We found that
compared with vehicle injection, cotreatment of either ML246
or Rg2 with WIN potently rescued the pain-relieving effect of
WIN in WT mice on d 14 to a d 1-like level (i.e., before
repeated dosage) (Fig. 5A, Video S10-S12), suggesting that the
autophagy-inducing compounds prevent analgesic tolerance
induced by chronic WIN administration. The cotreatment regi-
men did not alter body weight of the mice (Fig. S4A). To con-
firm the findings with pharmacological inducers, we further
asked whether autophagy induction by physiological methods
also rescues cannabinoid tolerance. We adopted 2 methods that
activate autophagy in mouse brain:22,27 the first is daily volun-
tary exercise by use of running wheels, which allows mice to
run for approximately 1 km/night; and the second is a “2-day
on/1-day off” periodic starvation protocol, in which mice were
subjected to cycles of 48-h fasting followed by 24-h feeding that
allowed them to return to normal weight in each cycle (Fig. 5B,
Fig. S4B).
Although the increase in autophagosome formation was not
significant in the brain (frontal cortex) of GFP-LC3 mice after
a single bout of 48-h fasting as previously reported using fluo-
rescence microscopy (Fig. S4C),9 we observed a cumulative
effect on autophagy induction in the same brain region after
multiple rounds of alternating fasting and feeding, demon-
strated by a significant induction of GFP-LC3 puncta in the
frontal cortex after 4 cycles of “2-day on/1-day off” starvation
(Fig. S4C). Although the exact mechanism of this additive effect
is currently unclear, we propose that it may be due to a rela-
tively stable glucose supply and low metabolism in the brain
(compared to muscle and liver), leading to slow formation/
turnover of autophagosomes that can be detected after repeated
induction. This hypothesis is supported by our observation that
skeletal muscle, which has high metabolic activity, does not
show much cumulative effect with regard to autophagy induc-
tion by periodic starvation cycles (Fig. S4C). At the end of
chronic WIN treatment, similar to mice treated with
autophagy-inducing compounds, mice undergoing daily run-
ning or intermittent fasting showed significantly higher sensi-
tivity to the analgesic effects of WIN (Fig. 5C, Video S13-S15),
suggesting that physiological autophagy inducers, such as exer-
cise and starvation, prevent analgesic tolerance as well. Alto-
gether, these data suggest that both pharmacological and
physiological autophagy inducers prevent cannabinoid toler-
ance to repeated dosage.
Autophagy induction preserves brain CNR1 level and
activity in response to chronic cannabinoids
To investigate whether restoration of CNR1 signaling underlies
the behavioral regulation by autophagy activation, we analyzed
Figure 5. Autophagy activation either pharmacologically or physiologically pre-
vents WT mice from developing behavioral tolerance to repeated cannabinoid dos-
age. (A) Analgesic tolerance of WT mice simultaneously treated with daily WIN and
vehicle, ML246, or Rg2 for 14 d. (B) Periodic fasting scheme. WT mice underwent
48-h fasting followed by 24-h feeding cycles during chronic WIN treatment. (C)
Analgesic tolerance of WT mice housed under normal conditions or subjected to
either “2 days on–1 day off” periodic starvation or running-wheel exercise, with
daily WIN treatment for 14 d. N D 8–14 mice/group. Results represent mean § s.e.
m. , P < 0.05; , P < 0.01; , P < 0.001 (t-test).
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the level and functionality of CNR1 in mouse brain after co-
administration of chronic cannabinoids and autophagy
inducers. Consistent with behavioral sensitization to WIN, after
chronic WIN treatment we detected higher levels of CNR1 in
the brain of mice concurrently treated with ML246 or Rg2
(Fig. 6A), or fasted or exercised (Fig. 6B), which were compara-
ble to the brain CNR1 level prior to chronic cannabinoid expo-
sure (Fig. 1A). To determine whether the increased level of
CNR1 represents CNR1 resensitization in the brain, we
analyzed the agonist-induced phosphorylation of signaling kin-
ases downstream of CNR1 after chronic WIN exposure. We
found that repeated WIN treatment decreased activation of
CNR1 signaling induced by agonists (Fig. 6C), whereas
autophagy induction, either pharmacologically by ML246 or
Rg2, or physiologically by starvation or exercise, rescued the
CNR1 signaling in spite of repeated WIN dosage, demonstrated
by increased phosphorylation of MAP2K and MAPK8/9
(Fig. 6D-E). Thus, these findings suggest that activating
Figure 6. Autophagy activation prevents chronic cannabinoid-induced CNR1 reduction and dysfunction in the brain. (A) Brain CNR1 levels of WT mice simultaneously
treated with daily WIN and vehicle, ML246 or Rg2 for 14 d. (B) Brain CNR1 levels of WT mice housed under normal conditions or subjected to either “2 days on–1 day off”
periodic starvation or running-wheel exercise, with daily WIN treatment for 14 d. Western blot images (left) and quantification (right) of 3 mice in each group are shown.
(C) Decreased CNR1 signaling after chronic WIN treatment. WT mice were treated with either daily WIN or vehicle for 14 d, and then subjected to an acute dosage of WIN
1 h prior to collection of brain samples. Western blot images (upper) and quantification (lower) of 3 mice in each group are shown. (D and E) Pharmacological (ML246 or
Rg2) and physiological (starvation or exercise) inducers of autophagy maintain CNR1 signal transduction in mouse brain after chronic agonist exposure. (D) WT mice were
treated as in (A), and then received an acute dosage of WIN 1 h prior to western blot analyses on brain lysates. (E) WT mice were treated as in (B), and injected with acute
WIN 1 h prior to western blot analyses on brain lysates. Western blot images (upper) and quantification (lower) of 3 mice in each group are shown. Results represent
mean § s.e.m. , P < 0.05; , P < 0.01; , P < 0.001 (t-test).
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autophagy pharmacologically or physiologically effectively
improves CNR1 signaling after chronic cannabinoid exposure.
Discussion
Our findings characterized an autophagy gene as a novel regu-
lator of drug-responsive behaviors, and linked autophagy for
the first time to CNR1 sensitization and drug tolerance to can-
nabinoids, a substance that has emerged as a major medical
and social challenge in recent decades. We demonstrated that
BECN2 is a new target in the prevention of tolerance to
repeated cannabinoid dosage, and developed the concept of
activating autophagy as an anti-tolerance therapeutic method.
Furthermore, we identified novel autophagy-inducing com-
pounds that achieve this goal by biochemically manipulating
the BECN2-GPRASP1 protein complex, which may serve as
candidate drug compounds to strengthen the pain-relieving
effects of cannabinoids for chronic usage. Notably, we also
found that periodic starvation and daily exercise are effective to
disrupt the BECN2-GPRASP1 interaction and to prevent mice
from cannabinoid tolerance after repeated usage, although we
cannot rule out that in the cases of daily exercise and alternat-
ing fasting/feeding, BECN2- or autophagy-independent mecha-
nisms may also contribute to the anti-toleranceanti-tolerance
effects or changes on CNR1 levels and signaling. To test this
hypothesis, further studies using mutant mice deficient in early
initiation of autophagy by starvation or exercise are required.
Furthermore, to conclusively establish a causal relationship
between BECN2-GPRASP1 binding and cannabinoid tolerance,
it is necessary to directly disrupt the BECN2-GPRASP1 interac-
tion or specifically perturb the BECN2 function in autophagy
in vivo, by generation of knock-in mice containing loss-of-
interaction mutations in BECN2 with either GPRASP1 or the
autophagy machinery.
Cannabinoids can serve as promising therapeutics in many
clinical occasions, such as alternative pain-relieving drugs for
patients who develop tolerance to opioid medication. Yet canna-
binoids’ own potential of drug tolerance and dependence limits
the medical use, which is sometimes a neglected issue due to the
notion that cannabis may not cause as strong tolerance and
dependence as some other drugs of abuse, such as opioids. Here
our findings opened up many unanswered questions on analgesic
tolerance to cannabinoids for further investigation. For example,
drug tolerance is likely to develop at different kinetics to various
CNR1 agonists of different efficacy;28 thus, in addition to
WIN55,212–2, which is a highly potent CNR1 agonist, it will be
essential to study whether the pharmacological or physiological
autophagy inducers mediate the same effects on high doses of the
natural cannabinoid THC (tetrahydrocannabinol) and other syn-
thetic CNR1 agonists developed for therapeutic use. It is also
important to analyze the role of BECN2 and autophagy in the reg-
ulation of analgesic tolerance to cannabinoids in disease models
of inflammatory or neuropathic pain,29-31 as thermal pain gener-
ated in the analgesic tolerance tests may not exactly mimic these
types of clinical pain. Thus, future studies will involve surgical- or
chemical-stimulation of inflammatory or neuropathic pain using
the Becn2 heterozygous KO mouse model. Finally, given that
BECN2 regulates the degradation of several additional drug-
responsive GPCRs besides CNR1,8 such as DRD2 (dopamine
receptor D2) and OPRD1 (opioid receptor, delta 1), the current
knowledge on cannabinoid tolerance may open up a new direc-
tion for studying autophagy in tolerance or dependence to drugs
of abuse targetingmany other BECN2-regulated receptors.
Materials and methods
Mice
All mice were in the C57BL/6J background and housed on a 12-
h light/dark cycle. The global Becn2C/¡ and Becn1C/¡ heterozy-
gous knockout mice have been described previously.8,32 All ani-
mal protocols were approved by the Northwestern University
Institutional Animal Care and Use Committee (IACUC).
Cell lines
HEK293 and HeLa cell lines were obtained from ATCC, and
stable FLAG-CNR1 HEK293 cells were from J. Whistler (Uni-
versity of California, San Francisco). Cells were cultured in
Dulbecco’s modified Eagle’s medium (ThermoFisher Scientific,
11965) supplemented with 10% fetal bovine serum (Thermo-
Fisher Scientific, 16140071).
Drug treatment
For in vivo use, WIN55,212–2 (Sigma-Aldrich, W102), ML246
(synthesized in-house) and Rg2 (purified in-house) were dis-
solved in a solvent containing 5% NMP (Sigma-Aldrich,
494496), 20% PEG400 (EMD Millipore, PX1286B) and 75% of
a 10% solution of HP-b-CD (Tokyo Chemical Industry,
H0979) in water, and injected intraperitoneally at the dosage of
2 mg/kg, 10 mg/kg, and 20 mg/kg body weight, respectively.
For cell culture use, WIN55,212–2 and ML246 were dissolved
in 100% DMSO (Fisher Scientific, BP231) and Rg2 was dis-
solved in 10% DMSO and used at the concentration of 1 mM,
0.5 mM and 100 mM, respectively. Bafilomycin A1 (Sigma-
Aldrich, B1793) was dissolved in 100% DMSO and used at
100 nM in cells.
Chronic WIN55,212–2 treatment and analgesic tolerance
test
The analgesic effect of the synthetic cannabinoid drug
WIN55,212–2 was measured by the latency time taken by mice
to feel the pain generated by an infrared beam and withdraw
their paw using the Hargreaves apparatus. Paw withdrawal was
detected and timed automatically by a fiber optic sensor.
According to the paradigm shown in Figure 1B, 8-wk-old male
mice were treated with WIN55,212–2 once per day at the dos-
age of 2 mg/kg body weight by intraperitoneal injection for 14
d continuously. On d 0, baseline pain sensitivity of the mice
was measured without injection of WIN55,212–2. At the begin-
ning (d 1) and the end (d 14) of chronic WIN55,212–2 treat-
ment, an acute bout of 2 mg/kg WIN55,212–2 was injected into
mice intraperitoneally 1 h prior to the analgesic tolerance test.
Data are shown as the percentage of time taken by each mouse
on d 0.
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Cyclic AMP measurement
Intracellular cAMP levels were analyzed in HEK293 cells stably
expressing FLAG-CNR1 by the cAMP-Glo assay kit (Promega,
V1681). Briefly, 40,000 cells/well were cultured in a 96-well
plate in triplicate, and treated with either cAMP stabilizers
0.5 mM IBMX (Sigma-Aldrich, I5879) and 1 mM forskolin
(Sigma-Aldrich, F6886) alone for 120 min, or with 1 mM
WIN55,212–2 plus IBMX and forskolin for 120 min, followed
by a phosphate-buffered saline (PBS; Sigma-Aldrich, D8537)
wash and 200 nM rimonabant (Cayman Chemical, 9000484)
treatment for 30 min, and then another 20 min incubation with
1 mM WIN55,212–2 in the presence of IBMX and forskolin.
The cells were subsequently lysed and cAMP production was
measured following the manufacturer’s instruction.
CNR1 trafficking and recycling by antibody pulse-chase
assay
The antibody-feeding immunofluorescence internalization and
recycling assays were performed essentially as previously
described.33,34 Briefly, HEK293 cells stably expressing FLAG-
CNR1 were grown on chamber slides, and incubated with
3.5 mg/ml M1 anti-FLAG antibody (Sigma-Aldrich, F3040) for
30 min. The cells were either directly fixed and immunostained
as below as “0 min” control, or treated with the CNR1 agonist
WIN55,212–2 (1 mM) for 30 min or 60 min and then washed
with calcium-free PBS (Sigma-Aldrich, D8537) to strip off the
residual noninternalized M1 antibody (M1-FLAG binding is
calcium-dependent). The cells were subsequently fixed in 2%
paraformaldehyde (PFA; Sigma-Aldrich, P6148), permeabilized
with 0.5% Triton X-100 (Bio-Rad, 161–0407), and then immu-
nostained with anti-EEA1 (ThermoFisher Scientific, MA5–
14794) or anti-LAMP1 (Cell Signaling Technology, 9091) anti-
body for imaging. An Alexa Fluor 488-conjugated secondary
antibody (ThermoFisher Scientific, A-21202) was used to detect
FLAG and an Alexa Fluor 594-conjugated secondary antibody
(ThermoFisher Scientific, A-11037) was used to detect EEA1
and LAMP1. For recycling experiments, after incubation with
M1 anti-FLAG antibody, cells were either fixed directly as
“0 min” control, or treated with WIN55,212–2 (1 mM) for
30 min, 140 min or 180 min, and then washed with calcium-
free PBS to strip off the non-internalized M1 antibody. To
detect recycled CNR1 (“140 minC30 min washout”), cells were
treated with the antagonist rimonabant (200 nM) for 30 min
following the 140 min-agonist treatment and M1 antibody
strip-off. The cells were fixed and permeablized as described
above.
Co-immunoprecipitation (co-IP)
For co-IP in cell culture, cells were lysed in lysis buffer contain-
ing 50 mM Tris-HCl, pH 7.4 (Sigma-Aldrich, 252859),
150 mM NaCl (Fisher Scientific, S271), 1 mM EDTA (Fisher
Scientific, BP2482), 0.9% Triton X-100, Halt protease inhibitor
cocktail (ThermoFisher Scientific, 1861279) and Halt phospha-
tase inhibitor cocktail (ThermoFisher Scientific, 78427), and
subjected to immunoprecipitation with anti-FLAG antibody
(Sigma-Aldrich, F3165). Eluates were subjected to western blot
analyses with anti-FLAG-HRP (Sigma-Aldrich, A8592) and
anti-GPRASP1 (Prestige Antibodies, HPA000161) antibodies.
The Atg13, Rb1cc1 and Ulk1 siRNAs used for co-IP experi-
ments were purchased from Cell Signaling Technology (M-
020765-01-0005, M-021117-01-0005, and M-005049-00-0005,
respectively). For co-IP in mouse brain, whole brain was dis-
sected and homogenized in the above lysis buffer and subjected
to immunoprecipitation with a polyclonal anti-mouse BECN2
antibody (custom made by GenScript Corporation). Eluates
were separated and detected by anti-mouse BECN2 antibody
and anti-GPRASP1 antibody using the ONE-HOUR Western
Detection Kit (GenScript Corporation, L00204C) following the
manufacturer’s instruction.
Autophagy analyses
HeLa cells stably expressing GFP-LC3 were cultured in normal
medium, starvation (Earle’s balanced salt solution; Sigma-
Aldrich, E7510) medium, or normal medium with the indicated
drugs for 3 h or 16 h. The cells were fixed with 2% PFA for
20 min, and GFP-LC3 puncta were quantified by fluorescence
microscopy.35 For assessment of autophagy in vivo, 8-wk-old
male GFP-LC3 mice were subjected to 48-h fasting or 4 cycles
of “2-day on/1-day off” fasting, or treated with the indicated
drugs (5 mg/kg ML246 and 20 mg/kg Rg2) once daily for 3 d
by intraperitoneal injection, and then anaesthetized and per-
fused with 4% PFA. Brain samples were fixed in 4% PFA over-
night, 15% sucrose (Sigma-Aldrich, S0389) for 4 h and 30%
sucrose overnight before frozen sections were prepared. The
number of GFP-LC3 puncta per unit area of tissue was quanti-
fied by fluorescence microscopy.36 Autophagy in vivo was also
analyzed by western blot analysis of brain tissue extracts with
antibodies against LC3 and SQSTM1 (see below for details).
Western blot analyses
Cell or mouse brain extracts were prepared in RIPA buffer
(Sigma-Aldrich, R0278) containing Halt protease inhibitor
cocktail and Halt phosphatase inhibitor cocktail, and subjected
to western blot analysis with anti-human BECN2 (ProSci Inc.,
7989), anti-LC3 (Novus Biologicals, NB100-2220), anti-
SQSTM1 (Abnova, H00008878-M01), anti-CNR1 (Cayman
Chemical, 101500), anti-MAP2K1/2 (Cell Signaling Technol-
ogy, 8727), anti-phosphorylated-MAP2K1/2 (Cell Signaling
Technology, 9154), anti-MAPK8/9 (Cell Signaling Technology,
9258), anti-phosphorylated-MAPK8/9 (Cell Signaling Technol-
ogy, 4668), anti-ATG13 (Cell Signaling Technology, 13273),
anti-RB1CC1 (Cell Signaling Technology, 12436), anti-ULK1
(Cell Signaling Technology, 8054) and anti-ACTB/b-actin-
HRP (Santa Cruz Biotechnology, sc-47778 HRP) antibodies.
Band intensity of western blot gel lanes was measured by
ImageJ.
Statistical analyses
P  0.05 was considered statistically significant in two-tailed,
unpaired Student t test. The investigator was blinded to the
group allocation during experiments, except for the Becn1C/¡
heterozygous knockout mice, as they are distinguishable due to
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a brown coat color rather than black. No animals were excluded
from the analyses.
Abbreviations
ATG13 autophagy- related 13
BECN1 Beclin 1, autophagy related
cAMP cyclic adenosine monophosphate
CNR1 cannabinoid receptor 1 (brain)
CRISPR clustered regularly-interspaced short palin-
dromic repeats
GPCR G protein-coupled receptor
GPRASP1 G protein-coupled receptor associated sort-
ing protein 1
KO knockout
MAP1LC3/LC3 microtubule-associated protein light chain 3
MAPK mitogen-activated protein kinase
MAP2K1/2 mitogen-activated protein kinase kinase 1/2
MEFs mouse embryonic fibroblasts
RB1CC1 RB1-inducible coiled-coil 1
SQSTM1 sequestosome 1
ULK1 unc-51 like kinase 1
WIN WIN55,212–2
WT wild-type
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